Teva Pharmaceutical Industries (TEVA) In-Depth Stock Report
The world's largest generics maker pivoting to innovative medicines, priced on debt reduction and the growth of key branded drugs.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Branded products grow strongly.
- Leverage falls quickly.
- Biosimilars add margin.
- Cost cuts expand margins.
- Teva is the largest generics maker pivoting to innovative medicines.
- Debt reduction and branded growth are central.
- Leverage and generic pricing are the main risks.
- Branded sales and leverage are the key numbers.
- Teva is a global generics and specialty pharmaceutical company with a large portfolio and manufacturing network.
- It sells branded drugs for neurological and psychiatric conditions and for migraine.
- The balance sheet is heavily indebted after a large acquisition and opioid and pricing litigation.
- A pivot strategy aims to grow innovative products while streamlining generics operations.
- The equity debate is whether branded growth and cost cuts can improve margins and reduce leverage.
Executive Summary
Teva's scale in generics gives it a broad international presence and access to hospitals and pharmacies, but generic pricing is competitive.
The company has been reducing debt through divestitures and cash flow, improving its financial position.
Branded products for migraine and other neurological conditions are a source of growth, offsetting decline in older brands.
Biosimilars and complex generics offer potentially higher-margin opportunities within the generics portfolio.
The realistic thesis: a turnaround story with improved balance-sheet health, whose valuation depends on branded growth and stabilization of generic pricing.
Industry & Market Backdrop
The broader competitive and macro environment TEVA operates in — context a pure valuation table can't convey on its own.
Generic pricing in the U.S. has stabilized after a long period of erosion, but competition remains intense.
Biosimilars are an emerging opportunity as biologic patents expire.
Opioid and other litigation created significant liabilities that are being resolved.
Migraine treatments have grown as a class, with competition among newer drugs.
Manufacturing cost and supply chain reliability matter in generics.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/TEVA. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Generics for the U.S., Europe, and international markets.
Specialty medicines in neuroscience, including migraine and movement disorders.
Biosimilars and complex generics.
An active pharmaceutical ingredient supply business.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
This large unit provides breadth and steady cash flow. Pricing and portfolio mix determine margins.
Branded products, including migraine and neurological drugs, offer better margins. Growth here is key to the strategy.
Biosimilars provide long-term growth if launched successfully. API sales add scale and manufacturing integration.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
Debt reduction is the top priority.
Divestitures of non-core businesses raised cash.
Litigation settlement payments affect cash flow.
Dividends were suspended earlier, and share buybacks are not a focus.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Leadership is executing a restructuring and pivot to growth.
Management has set targets for revenue growth, margins, and leverage.
Governance is conventional for a company with a turnaround narrative; review the proxy.
Credibility rests on delivering the pivot plan.
See exactly how we get TEVA's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our DCF Model | High | |
| Our P/E Based | Medium | |
| Our Book Value Based | Low | |
| Graham Number | Low | |
| ROIC Based | Low | |
| FCF Yield Based | High |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this Teva Pharmaceutical Industries report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Branded products grow strongly.
- Leverage falls quickly.
- Biosimilars add margin.
- Cost cuts expand margins.
- Litigation overhangs fade.
- Generic pricing erodes.
- Branded products face competition.
- Debt remains high.
- Litigation costs rise.
- Restructuring falls short.
Related Reports
In-depth reports for other names in Teva Pharmaceutical Industries's comparable set.
4 catalysts and 4 risks we're tracking for TEVA
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this Teva Pharmaceutical Industries report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- Branded revenue grows steadily
- Debt falls faster than planned
- Margins expand
- Branded launches disappoint
- Generic pricing worsens
- Litigation costs escalate
Competitive Positioning
Teva's moat is generics scale, distribution, and a complex-generics portfolio.
Viatris, Sandoz, Sun Pharma, and Dr. Reddy's compete in generics.
Branded competition includes other migraine and neurology drugs.
The vulnerability is leverage and generic price erosion.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want a leveraged turnaround in pharma.
- Skip it if you want stable growth or dislike leverage.
- Track debt and branded growth.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "TEVA fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where TEVA is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.